10-Q: Pyxis Oncology Reports Q3 2025 Results, Focuses on HNSCC

Pyxis Oncology reported increased net losses and a going concern warning, while advancing its lead oncology candidate, micvotabart pelidotin, with positive preliminary HNSCC clinical data and Fast Track Designation.

Summary

• Reported a net loss of $22.0 million for the three months ended September 30, 2025, compared to $21.2 million for the same period in 2024.
• Reported a net loss of $61.5 million for the nine months ended September 30, 2025, compared to $41.8 million for the same period in 2024.
• Accumulated deficit reached $425.1 million as of September 30, 2025.
• Cash, cash equivalents, restricted cash, and short-term investments totaled $77.7 million as of September 30, 2025.
• Recognized $2.8 million in milestone revenue for the nine months ended September 30, 2025, due to regulatory approval of Suvemcitug in China.
• Research and development expenses increased to $52.0 million for the nine months ended September 30, 2025, from $44.7 million in the prior year, primarily driven by micvotabart pelidotin development.
• General and administrative expenses decreased to $17.0 million for the nine months ended September 30, 2025, from $20.3 million in the prior year.
• Net cash used in operating activities increased to $53.1 million for the nine months ended September 30, 2025, from $38.4 million in the prior year.
• All net proceeds from the October 2021 IPO have been utilized.
• The company has $106.2 million remaining capacity under its At-The-Market (ATM) offering program as of September 30, 2025, with no shares sold during the quarter.
• Preliminary data from the Phase 1 dose escalation study (PYX-201-101 Part 1) of micvotabart pelidotin showed a 50% objective response rate (ORR) and 100% disease control rate (DCR) in six efficacy-evaluable R/M HNSCC patients at therapeutically active doses.
• Micvotabart pelidotin received Fast Track Designation from the FDA in February 2025 for R/M HNSCC.
• Initiated the dose expansion phase (Part 2) of the PYX-201-101 monotherapy study in early January 2025, focusing on R/M HNSCC.
• Initiated a Phase 1/2 combination study (PYX-201-102) with Merck's KEYTRUDA (pembrolizumab) in early January 2025 for advanced solid tumors, including R/M HNSCC.
• Paused the clinical development of PYX-106 in December 2024.

Sentiment

Score: 4

Explanation: While clinical data for the lead candidate is promising and received Fast Track Designation, the significant increase in net losses, high cash burn, and explicit 'going concern' warning create substantial financial uncertainty. The positive clinical developments are overshadowed by the immediate and critical need for additional capital.

Positives

• Micvotabart pelidotin (MICVO) demonstrated positive preliminary Phase 1 data in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), achieving a 50% objective response rate (ORR) and 100% disease control rate (DCR) in a subset of patients.
• MICVO received Fast Track Designation from the FDA in February 2025 for R/M HNSCC, potentially accelerating its development and review.
• The company initiated two new clinical trial phases for MICVO in early January 2025: a monotherapy dose expansion study and a Phase 1/2 combination study with Merck's KEYTRUDA, indicating active pipeline progression.
• Translational data presented at ESMO and AACR-NCI-EORTC in October 2025 provided deeper insights into MICVO's unique mechanism of action, including direct tumor cell killing, bystander killing, and immunogenic cell death, supporting its potential as monotherapy and in combination with anti-PD-1 therapy.
• Received a $2.8 million milestone revenue (net of tax) from the regulatory approval of Suvemcitug in China, demonstrating value from out-licensing agreements.

Negatives

• Incurred significant net losses of $61.5 million for the nine months ended September 30, 2025, an increase from $41.8 million in the prior year.
• The company has an accumulated deficit of $425.1 million as of September 30, 2025.
• Current cash, cash equivalents, and short-term investments of $77.7 million are not sufficient to fund operations over the next 12 months, raising substantial doubt about the company's ability to continue as a going concern.
• Total revenues significantly decreased to $2.8 million for the nine months ended September 30, 2025, from $16.1 million in the prior year, primarily due to the absence of royalty revenues and sale of royalty rights present in 2024.
• Net cash used in operating activities increased to $53.1 million for the nine months ended September 30, 2025, indicating a higher cash burn rate.
• Clinical development of PYX-106 was paused in December 2024, reducing the diversity of the pipeline.

Risks

• The company is a clinical-stage oncology company with a limited operating history and has incurred significant losses, anticipating continued losses and may never achieve profitability.
• Substantial additional capital is required to finance operations; inability to raise capital could force delays, reductions, or elimination of research and product development programs.
• Heavy dependence on the success of micvotabart pelidotin, which is in early clinical development; failure in trials or regulatory approval would materially and adversely affect the business.
• Product candidates may fail in development or suffer delays, materially and adversely affecting commercial viability.
• Product candidates may cause undesirable and unforeseen side effects or have other properties impacting safety, potentially halting clinical development or limiting commercial potential.
• Significant competition from other biotechnology and pharmaceutical entities could adversely affect operating results.
• Clinical testing and product development is a lengthy, expensive, and uncertain process with unpredictable outcomes.
• The regulatory approval processes of the FDA and other foreign authorities are lengthy, time-consuming, and inherently unpredictable.
• Failure to attract and retain qualified senior management and key scientific personnel could materially and adversely affect the business.
• Reliance on third parties to manufacture product candidates; any failure by manufacturers could delay or impair clinical trials, regulatory licensure, or commercialization.
• Inability to obtain or protect intellectual property in and to product candidates could hinder effective competition.
• Breach of license, collaboration, or other agreements could lead to damages or loss of intellectual property rights.
• Actual or perceived failures to comply with data protection, privacy, and security laws could adversely affect business, operations, and financial condition.
• Information technology systems, or those of third parties, may be compromised, leading to additional costs, liabilities, and disruption.
• Product liability risks are significant, and insufficient insurance coverage could have a material adverse effect.
• Unfavorable pricing regulations or third-party coverage/reimbursement practices could harm the business.
• Enacted and future healthcare legislation may increase the difficulty and cost of clinical programs and commercialization.
• Disruptions at government agencies (FDA, SEC) could hinder their ability to perform normal business functions.
• Economic, political, regulatory, and other risks associated with conducting business internationally, including manufacturing in China and potential trade restrictions.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for the foreseeable future as it advances product candidates through development and clinical trials. Current cash, cash equivalents, and short-term investments are estimated to fund operations into the second half of 2026, but additional funding will be required beyond that. The company plans to hold discussions with the FDA to align on the optimal monotherapy dose for micvotabart pelidotin under Project Optimus, with next steps for clinical development in R/M HNSCC expected in Q4 2025. Preliminary data from the monotherapy dose expansion and combination studies for R/M HNSCC are also anticipated in Q4 2025.

Management Comments

• We believe the totality of our preliminary clinical, preclinical, and translational data support further development of micvotabart pelidotin in both monotherapy and in combination studies.
• We have decided to prioritize our resources to focus the next stage of development on characterizing the R/M HNSCC efficacy signal for micvotabart pelidotin.
• While we remain optimistic to obtain additional funding in the near future, the current available cash, cash equivalents and short-term investments, will not be sufficient to fund our operations over the next 12 months from the date of this Quarterly Report on Form 10-Q.

Industry Context

Pyxis Oncology operates in the highly competitive clinical-stage oncology sector, focusing on novel antibody-drug conjugates (ADCs) and immunotherapies. The company's lead candidate, micvotabart pelidotin, targets Extradomain-B Fibronectin (EDB+FN), a non-cellular component of the tumor extracellular matrix, representing a differentiated approach compared to conventional ADCs that target cell surface antigens. The positive preliminary data in R/M HNSCC and Fast Track Designation position Pyxis within a rapidly evolving landscape where combination therapies, particularly with PD-1 inhibitors like KEYTRUDA, are becoming standard. The pausing of PYX-106 reflects a common industry trend of pipeline prioritization to conserve capital and focus on lead assets with the strongest signals, especially for companies facing liquidity challenges. The competitive landscape for HNSCC includes established players and emerging agents with various mechanisms, including EGFR and Nectin-4 targeting ADCs, highlighting the need for strong efficacy and safety profiles to gain market share.

Comparison to Industry Standards

• Micvotabart pelidotin's 50% ORR and 100% DCR in R/M HNSCC patients (n=6) at therapeutically active doses are promising for a heavily pre-treated population, especially when compared to historical response rates for later-line HNSCC therapies, which can be significantly lower.
• The company's focus on EDB+FN as a target for its ADC, micvotabart pelidotin, differentiates it from many conventional ADCs that target tumor cell surface antigens. This unique mechanism of action, aiming for extracellular cleavage and bystander killing, could offer advantages over competitors like Corbus Pharmaceuticals' nectin-4 targeting ADC, CRB-701, which uses a similar MMAE payload but may rely more on traditional ADC internalization.
• The collaboration with Merck for a KEYTRUDA combination study aligns with industry trends of combining novel agents with established immune checkpoint inhibitors to enhance efficacy, a strategy employed by numerous oncology developers.
• The company faces competition from other agents targeting HNSCC, such as Merus's petosemtamab (EGFR/LGR5 biclonic), Bicaras's ficerafusp alfa (EGFR/TGF-beta bifunctional), and Johnson & Johnson's amivantamab (EGFR/cMET bispecific antibody), which are also targeting patient populations of interest to micvotabart pelidotin. The preliminary efficacy data for micvotabart pelidotin will need to be further validated in larger trials to demonstrate competitive differentiation against these and other emerging therapies.
• The company's financial position, with a going concern warning and significant accumulated deficit, is a common challenge for clinical-stage biopharmaceutical companies, often requiring substantial capital raises to fund lengthy and expensive development programs, similar to many peers in the early-stage biotech sector.

Legal Proceedings

• The company is not currently a party to any material legal proceedings and is not aware of any pending or threatened legal proceeding against it that could have an adverse effect on its business, operating results, or financial condition.

Related Party Transactions

• The company has license agreements with the University of Chicago and Pfizer Inc. for intellectual property rights related to its product candidates, including micvotabart pelidotin.
• The company assumed out-licensing agreements, including the Simcere License and Collaboration Agreement, through the acquisition of Apexigen, Inc.

Stakeholder Impact

• Shareholders face significant dilution risk from potential future equity offerings required to fund operations.
• Shareholders face substantial risk to their investment due to the company's 'going concern' warning and inability to fund operations for the next 12 months with current capital.
• Employees may face uncertainty regarding job security if the company is unable to secure additional funding or is forced to curtail programs.
• Customers (future patients) could benefit from the continued development of micvotabart pelidotin, especially given the positive preliminary data in R/M HNSCC and Fast Track Designation.
• Suppliers and creditors face increased risk due to the company's liquidity challenges and potential for delayed payments or reduced orders if funding is not secured.
• Collaboration partners (e.g., Merck) may see their programs impacted if Pyxis Oncology's financial condition deteriorates or if development timelines are affected by funding issues.

Next Steps

• Disclose preliminary data from the micvotabart pelidotin monotherapy R/M HNSCC expansion cohorts in the fourth quarter of 2025.
• Disclose preliminary data from the micvotabart pelidotin and KEYTRUDA combination study for R/M HNSCC patients in the fourth quarter of 2025.
• Hold discussions with the FDA to align on the optimal monotherapy dose for micvotabart pelidotin under Project Optimus.
• Announce next steps in the clinical development plan for micvotabart pelidotin for R/M HNSCC in the fourth quarter of 2025.
• Secure additional funding through public or private equity, convertible or debt financing, or collaboration agreements to continue operations beyond the second half of 2026.

Key Dates

Recommendation

The filing presents a mixed bag of promising clinical progress for micvotabart pelidotin, including positive preliminary Phase 1 data in HNSCC and Fast Track Designation, which are significant positive catalysts. However, these clinical positives are heavily counterbalanced by severe financial concerns, including increased net losses, a high cash burn rate, and an explicit 'going concern' warning, indicating that current capital is insufficient for the next 12 months. While the clinical data suggests potential, the immediate and substantial need for capital introduces significant financial risk and uncertainty. A seasoned investor would likely 'hold' to monitor the company's ability to secure necessary financing and to see if the promising clinical signals translate into sustained efficacy and safety in larger, later-stage trials, before committing further capital or divesting based solely on the current financial distress.

Keywords

Oncology, Biotechnology, Clinical Stage, ADC, Antibody-Drug Conjugate, micvotabart pelidotin, HNSCC, Head and Neck Squamous Cell Carcinoma, EDB+FN, Cancer Therapeutics, Clinical Trials, FDA Fast Track, Merck, KEYTRUDA, Pembrolizumab, SEC Filing, 10-Q, Financial Results, Going Concern, Biopharma